{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:02:19Z","timestamp":1789502539129,"version":"build-2803163510"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:p>\n                    The early efficacy of thrombolysis within 24 hours can accurately reflect its effectiveness, as it is less influenced by other factors. This study aimed to analyze the factors influencing the early efficacy of intravenous thrombolysis using recombinant tissue plasminogen activator (IV-rtPA). The clinical data of 225 acute ischemic stroke patients treated with IV-rtPA from December 2018 to June 2023 were analyzed retrospectively. Univariate analysis and multivariate logistic regression analysis were used to compare data between 2 groups. The effective group included 127 patients (49.8%), while the noneffective group had 128 patients (50.2%). Patients with a baseline National Institute of Health Stroke Scale (NIHSS) score below 10 and those who received IV-rtPA within 3 hours of acute ischemic stroke onset-to-treatment time (OTT) showed greater benefits (NIHSS, \u03c7\u00b2\u2005=\u2005110.434,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001; OTT, \u03c7\u00b2\u2005=\u200523.196,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). Univariate analysis revealed significant differences between the groups in gender (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.030), age (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), AF history (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.024), drinking history (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.026), FIB level (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.012), SBP level (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.046), OTT time (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), baseline NIHSS (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), and rtPA dose (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.012). Multivariate logistic regression analysis identified male gender (OR: 3.986, 95% CI: 1.727\u20139.201,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), drinking history (OR: 0.253, 95% CI: 0.124\u20130.671,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004), OTT (OR: 0.958, 95% CI: 0.948\u20130.969,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), baseline NIHSS scores (OR: 0.838, 95% CI: 0.785\u20130.895,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), and rtPA dose (OR: 385.527, 95% CI: 16.725\u20138886.741,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) as independent factors influencing early efficacy. Male gender, drinking history, baseline NIHSS score, OTT, and rtPA dose are independent factors affecting early thrombolysis efficacy. Age, AF history, high FIB level, and high SBP may also be potential risk factors.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045176","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:03:52Z","timestamp":1762211032000},"page":"e45176","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Factors affecting the early efficacy of intravenous thrombolysis using alteplase in acute ischemic stroke: A retrospective analysis of 255 cases"],"prefix":"10.1097","volume":"104","author":[{"given":"Jiwei","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"},{"name":"Department of Neurology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Neurology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangbo","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0234-215X","authenticated-orcid":false,"given":"Yunyun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1016\/S2214-109X(20)30069-3","article-title":"Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0\u00b75 million Chinese adults.","volume":"8","author":"Chen","year":"2020","journal-title":"Lancet Glob Health"},{"key":"R2-20260915","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1804492","article-title":"Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016.","volume":"379","author":"Feigin","year":"2018","journal-title":"N Engl J Med"},{"key":"R3-20260915","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.1963.03700040039009","article-title":"Ischemic cerebrovascular disease (stroke). Clinical investigation and management.","volume":"183","author":"Meyer","year":"1963","journal-title":"JAMA"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/S0140-6736(12)60738-7","article-title":"Recombinant tissue plasminogen activator for acute ischemic stroke: an updated systematic review and meta-analysis.","volume":"379","author":"Wardlaw","year":"2012","journal-title":"Lancet"},{"key":"R5-20260915","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(10)60634-4","article-title":"Alteplase for ischemic stroke \u2013 much sooner is much better.","volume":"375","author":"Saver","year":"2010","journal-title":"Lancet"},{"key":"R6-20260915","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(14)61917-6","article-title":"Alteplase for ischaemic stroke.","volume":"384","author":"Burrage","year":"2014","journal-title":"Lancet"},{"key":"R7-20260915","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke.","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"R8-20260915","first-page":"9708","article-title":"Effect of a modern stroke unit combined with recombinant human tissue-type plasminogen activator intravenous thrombolysis on ischemic cerebral infarction and its influence on limb motor function and activity of daily living.","volume":"13","author":"Wang","year":"2021","journal-title":"Am J Transl Res"},{"key":"R9-20260915","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1161\/STROKEAHA.107.510768","article-title":"Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST).","volume":"39","author":"Wahlgren","year":"2008","journal-title":"Stroke"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.","volume":"359","author":"Hacke","year":"2008","journal-title":"N Engl J Med"},{"key":"R11-20260915","first-page":"313","article-title":"Acute myocardial infarction in the young \u2013 the role of smoking. The investigators of the international tissue plasminogen activator\/streptokinase mortality trial.","volume":"16","author":"Barbash","year":"1995","journal-title":"Eur Heart J"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0735-1097(87)80115-8","article-title":"Factors influencing myocardial preservation after recombinant tissue plasminogen activator (rt-PA) in acute myocardial infarction.","volume":"10","author":"Rackley","year":"1987","journal-title":"J Am Coll Cardiol"},{"key":"R13-20260915","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4103\/0028-3886.82723","article-title":"Early outcome after intravenous thrombolysis in patients with acute ischemic stroke.","volume":"59","author":"Dharmasaroja","year":"2011","journal-title":"Neurol India"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199906103402302","article-title":"Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.","volume":"340","author":"Kwiatkowski","year":"1999","journal-title":"N Engl J Med"},{"key":"R15-20260915","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jemermed.2010.05.009","article-title":"Thrombolytic therapy for acute ischemic stroke beyond three hours.","volume":"40","author":"Carpenter","year":"2011","journal-title":"J Emerg Med"},{"key":"R17-20260915","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S1474-4422(09)70264-9","article-title":"Stroke treatment with alteplase given 3.0-4.5\u2009h after onset of acute ischemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.","volume":"8","author":"Bluhmki","year":"2009","journal-title":"Lancet Neurol"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0140-6736(07)60149-4","article-title":"Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.","volume":"369","author":"Wahlgren","year":"2007","journal-title":"Lancet"},{"key":"R19-20260915","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/jama.2020.26867","article-title":"Diagnosis and management of transient ischemic attack and acute ischemic stroke: a review.","volume":"325","author":"Mendelson","year":"2021","journal-title":"JAMA"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"e2120745","DOI":"10.1001\/jamanetworkopen.2021.20745","article-title":"Clinical characteristics, management, and in-hospital outcomes in patients with stroke or transient ischemic attack in China.","volume":"4","author":"Gu","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1161\/STROKEAHA.114.006222","article-title":"Impact of time to treatment on tissue-type plasminogen activator-induced recanalization in acute ischemic stroke.","volume":"45","author":"Muchada","year":"2014","journal-title":"Stroke"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1001\/jama.2013.6959","article-title":"Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke.","volume":"309","author":"Saver","year":"2013","journal-title":"JAMA"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","article-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6\u2009h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.","volume":"379","author":"Sandercock","year":"2012","journal-title":"Lancet"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(14)60584-5","article-title":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.","volume":"384","author":"Emberson","year":"2014","journal-title":"Lancet"},{"key":"R25-20260915","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1161\/STROKEAHA.109.552547","article-title":"Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.","volume":"40","author":"Lansberg","year":"2009","journal-title":"Stroke"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa1804355","article-title":"MRI-guided thrombolysis for stroke with unknown time of onset.","volume":"379","author":"Thomalla","year":"2018","journal-title":"N Engl J Med"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","article-title":"Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke.","volume":"380","author":"Ma","year":"2019","journal-title":"N Engl J Med"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/STROKEAHA.113.003898","article-title":"Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke.","volume":"45","author":"Xian","year":"2014","journal-title":"Stroke"},{"key":"R29-20260915","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1161\/STROKEAHA.109.554386","article-title":"Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials.","volume":"40","author":"Cucchiara","year":"2009","journal-title":"Stroke"},{"key":"R30-20260915","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.STR.0000227191.01792.e3","article-title":"Alteplase at 0.6\u2009mg\/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).","volume":"37","author":"Yamaguchi","year":"2006","journal-title":"Stroke"},{"key":"R31-20260915","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1515510","article-title":"Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke.","volume":"374","author":"Anderson","year":"2016","journal-title":"N Engl J Med"},{"key":"R32-20260915","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00415-019-09361-6","article-title":"Cumulative alcohol consumption and stroke risk in men.","volume":"266","author":"Duan","year":"2019","journal-title":"J Neurol"},{"key":"R33-20260915","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ejcn.2016.171","article-title":"New national data show alarming increase in obesity and noncommunicable chronic diseases in China.","volume":"71","author":"Wang","year":"2017","journal-title":"Eur J Clin Nutr"},{"key":"R34-20260915","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1212\/WNL.0000000000002078","article-title":"IV thrombolysis in patients with ischemic stroke and alcohol abuse.","volume":"85","author":"Gattringer","year":"2015","journal-title":"Neurology"},{"key":"R35-20260915","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3988\/jcn.2018.14.2.141","article-title":"The influence of sex in stroke thrombolysis: a systematic review and meta-analysis.","volume":"14","author":"Liu","year":"2018","journal-title":"J Clin Neurol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:03:24Z","timestamp":1789499004000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":34,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045176","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"2025-06-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}